Concordance Between Urine Drug Screening and Self-Reported Use in the Context of a Pragmatic Randomized-Controlled Trial in People with <i>Prescription-Type</i> Opioid Use Disorder: Concordance entre le dépistage de drogues dans l’urine et l’usage au

ObjectiveIn this study, we evaluated the concordance between urine drug screening (UDS) and self-reported use in a pragmatic randomized clinical trial.MethodsOur data was drawn from OPTIMA, a 24-week pragmatic multicentric open-label randomized-controlled trial comparing flexible take-home dosing of buprenorphine/naloxone to the methadone standard model of care for treating prescription-type opioid use disorder. A total of 272 participants were randomized (1:1 ratio) to methadone or buprenorphine/naloxone. Following treatment initiation, participants were followed-up every 2 weeks for 24 weeks. During each visit, participants provided urine samples for UDS and self-reported their substance use over the past 2 weeks. Self-reported use was dichotomized to align with UDS detection windows. Tetrachoric correlations and 2 × 2 contingency tables were used to estimate the sensitivity, specificity, positive predictive value and negative predictive value of self-reported use. A generalized linear mixed model assessed how substance type, time in the study, treatment assignment, study site, unstable housing, and sex impacted self-report accuracy.ResultsSignificant differences were found between substance types (<i>p</i> < 0.001) and study sites (<i>p</i> < 0.001). Fentanyl, cannabis, and amphetamines consistently showed the greatest concordance between measurement methods. Hydromorphone, oxycodone, heroin, and benzodiazepines had low sensitivity and low positive predictive value. Participants from Québec showed higher concordance between UDS and self-reported use compared to those from British Columbia, Alberta, and Ontario. There was no moderating effect of treatment assignment (<i>p</i> = 0.174), time in the study (<i>p</i> = 0.221), unstable housing (<i>p</i> = 0.733), or sex (<i>p</i> = 0.321) on the concordance between UDS and self-reported use.ConclusionsOur results indicate that concordance between UDS and self-reported use is impacted by several factors. Combining UDS and self-reported use could help provide a more accurate assessment of substance use.Clinical trial registrationThis study was registered in ClinicalTrials.gov (NCT03033732).

Authors

Institutions

Publication Details

Journal
The Canadian Journal of Psychiatry
Published
2025-08-28
DOI
https://doi.org/10.1177/07067437251367180
Primary Topic
Opioid Use Disorder Treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Concordance Between Urine Drug Screening and Self-Reported Use in the Context of a Pragmatic Randomized-Controlled Trial in People with Prescription-Type Opioid Use Disorder: Concordance entre le dépistage de drogues dans l’urine et l’usage au

Gabriel Bastien, Simon Dubreucq, Amani Mahroug, M. Eugenia Socías et al.
The Canadian Journal of Psychiatry
Opioid Use Disorder Treatment
article

Concordance Between Urine Drug Screening and Self-Reported Use in the Context of a Pragmatic Randomized-Controlled Trial in People with Prescription-Type Opioid Use Disorder: Concordance entre le dépistage de drogues dans l’urine et l’usage au

Gabriel Bastien, Simon Dubreucq, Amani Mahroug, M. Eugenia Socías, Christina McAnulty, Louis-Christophe Juteau, Didier Jutras‐Aswad, Bernard Le Foll, Anita Abboud
article en

Abstract

ObjectiveIn this study, we evaluated the concordance between urine drug screening (UDS) and self-reported use in a pragmatic randomized clinical trial.MethodsOur data was drawn from OPTIMA, a 24-week pragmatic multicentric open-label randomized-controlled trial comparing flexible take-home dosing of buprenorphine/naloxone to the methadone standard model of care for treating prescription-type opioid use disorder. A total of 272 participants were randomized (1:1 ratio) to methadone or buprenorphine/naloxone. Following treatment initiation, participants were followed-up every 2 weeks for 24 weeks. During each visit, participants provided urine samples for UDS and self-reported their substance use over the past 2 weeks. Self-reported use was dichotomized to align with UDS detection windows. Tetrachoric correlations and 2 × 2 contingency tables were used to estimate the sensitivity, specificity, positive predictive value and negative predictive value of self-reported use. A generalized linear mixed model assessed how substance type, time in the study, treatment assignment, study site, unstable housing, and sex impacted self-report accuracy.ResultsSignificant differences were found between substance types (<i>p</i> < 0.001) and study sites (<i>p</i> < 0.001). Fentanyl, cannabis, and amphetamines consistently showed the greatest concordance between measurement methods. Hydromorphone, oxycodone, heroin, and benzodiazepines had low sensitivity and low positive predictive value. Participants from Québec showed higher concordance between UDS and self-reported use compared to those from British Columbia, Alberta, and Ontario. There was no moderating effect of treatment assignment (<i>p</i> = 0.174), time in the study (<i>p</i> = 0.221), unstable housing (<i>p</i> = 0.733), or sex (<i>p</i> = 0.321) on the concordance between UDS and self-reported use.ConclusionsOur results indicate that concordance between UDS and self-reported use is impacted by several factors. Combining UDS and self-reported use could help provide a more accurate assessment of substance use.Clinical trial registrationThis study was registered in ClinicalTrials.gov (NCT03033732).

The Canadian Journal of PsychiatryVol. 71(1)
Centre for Addiction and Mental Health (CA), University of British Columbia (CA), University of Toronto (CA), British Columbia Centre on Substance Use (CA), Centre Hospitalier de l’Université de Montréal (CA), Waypoint Centre for Mental Health Care (CA), Université de Montréal (CA)
Canadian Institutes of Health Research
Openalex Percentile: Top 69%
Opioid Use Disorder Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.